| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nektar Therapeutics (NKTR) has 8 insiders with recent SEC Form 4 filings, including 1 buy and 10 sells. NKTR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 75.9K | $4.92M | - | |
| Other | 21.6K | $1.40M | - | |
| Other | 15.4K | $1.00M | -5,538 | |
| Dir | 8.0K | $518.7K | - | |
| Dir | 8.0K | $518.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2017 | Nicholson John | SVP &Chief Operating Officer | Sell | 3,177 | $19.32 | $61,379.64 | -1.4% | |
| Aug 16, 2017 | Labrucherie Gil M84 | SVP &Chief Financial Officer | Sell | 3,177 | $19.32 | $61,379.64 | -4.8% | |
| Aug 16, 2017 | Hora Maninder | SVP Pharma Dev &Mfg Ops | Sell | 2,956 | $19.32 | $57,109.92 | -4.8% | |
| Aug 16, 2017 | Gergel Ivan P. | SVP &Chief Medical Officer | Sell | 1,997 | $19.32 | $38,582.04 | -4.6% | |
| Aug 16, 2017 | Doberstein Stephen K | SVP &Chief Scientific Officer | Sell | 1,701 | $19.32 | $32,863.32 | -5.2% | |
| Aug 10, 2017 | Whitfield Roy A | Director | Buy | 35,000 | $17.95 | $628,250.00 | +35.7% | |
| Jul 18, 2017 | Gergel Ivan P. | SVP &Chief Medical Officer | Sale+OE | 54,920 | $21.10 | $1,158,812.00 | -55.8% | |
| Jul 14, 2017 | Lingnau Lutz | Director | Sale+OE | 30,000 | $20.76 | $622,800.00 | -56.1% | |
| Jul 12, 2017 | Gergel Ivan P. | SVP &Chief Medical Officer | Sale+OE | 45,080 | $21.08 | $950,317.75 | -34.1% | |
| Jun 7, 2017 | Nicholson John | SVP &Chief Operating Officer | Sale+OE | 101,700 | $19.24 | $1,956,708.00 | -30.9% |